2173 related articles for article (PubMed ID: 10223338)
1. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
2. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120.
Luo L; Li Y; Chang JS; Cho SY; Kim TY; Choi MJ; Cheong HS; Kim HJ; Ahn HJ; Min MK; Chun BH; Jung SM; Woo SG; Park SY; Kang CY
Virology; 1998 Jan; 240(2):316-25. PubMed ID: 9454705
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
4. Mapping of functional domains for HIV-2 gag assembly into virus-like particles.
Luo L; Li Y; Dales S; Kang CY
Virology; 1994 Dec; 205(2):496-502. PubMed ID: 7975251
[TBL] [Abstract][Full Text] [Related]
5. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles.
Wagner R; Deml L; Schirmbeck R; Niedrig M; Reimann J; Wolf H
Virology; 1996 Jun; 220(1):128-40. PubMed ID: 8659105
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
7. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities.
Tobin GJ; Li GH; Fong SE; Nagashima K; Gonda MA
Virology; 1997 Sep; 236(2):307-15. PubMed ID: 9325238
[TBL] [Abstract][Full Text] [Related]
8. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
[TBL] [Abstract][Full Text] [Related]
9. Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model.
Notka F; Stahl-Hennig C; Dittmer U; Wolf H; Wagner R
Biol Chem; 1999 Mar; 380(3):341-52. PubMed ID: 10223337
[TBL] [Abstract][Full Text] [Related]
10. Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies.
Luo L; Li Y; Cannon PM; Kim S; Kang CY
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10527-31. PubMed ID: 1438241
[TBL] [Abstract][Full Text] [Related]
11. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes.
McBurney SP; Young KR; Ross TM
Virology; 2007 Feb; 358(2):334-46. PubMed ID: 17011011
[TBL] [Abstract][Full Text] [Related]
12. Chimaeric HIV-1 subtype C Gag molecules with large in-frame C-terminal polypeptide fusions form virus-like particles.
Halsey RJ; Tanzer FL; Meyers A; Pillay S; Lynch A; Shephard E; Williamson AL; Rybicki EP
Virus Res; 2008 May; 133(2):259-68. PubMed ID: 18329748
[TBL] [Abstract][Full Text] [Related]
13. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
[TBL] [Abstract][Full Text] [Related]
14. Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.
Wagner R; Deml L; Schirmbeck R; Reimann J; Wolf H
Behring Inst Mitt; 1994 Dec; (95):23-34. PubMed ID: 7755506
[TBL] [Abstract][Full Text] [Related]
15. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain.
Deml L; Kratochwil G; Osterrieder N; Knüchel R; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):10-25. PubMed ID: 9300033
[TBL] [Abstract][Full Text] [Related]
16. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles.
Wagner R; Deml L; Fliessbach H; Wanner G; Wolf H
Virology; 1994 Apr; 200(1):162-75. PubMed ID: 7510434
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
Hewer R; Meyer D
Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
[TBL] [Abstract][Full Text] [Related]
18. Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicity.
Persson RH; Cao SX; Cates G; Yao FL; Klein MH; Rovinski B
Biologicals; 1998 Dec; 26(4):255-65. PubMed ID: 10403029
[TBL] [Abstract][Full Text] [Related]
19. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
20. Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.
Wagner R; Böltz T; Deml L; Modrow S; Wolf H
J Gen Virol; 1993 Jul; 74 ( Pt 7)():1261-9. PubMed ID: 7687647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
